Cargando…
Characterisation of circulating chromogranin A in human cancer patients.
The structure of circulating chromogranin A (CgA) of phaeochromocytoma patients was characterised and compared with that of CgA extracted from tumours. Size exclusion chromatography experiments provided evidence that CgA is present in the blood of different patients, as well as in tumour extracts, a...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075816/ https://www.ncbi.nlm.nih.gov/pubmed/8611427 |
_version_ | 1782138085421613056 |
---|---|
author | Corti, A. Gasparri, A. Chen, F. X. Pelagi, M. Brandazza, A. Sidoli, A. Siccardi, A. G. |
author_facet | Corti, A. Gasparri, A. Chen, F. X. Pelagi, M. Brandazza, A. Sidoli, A. Siccardi, A. G. |
author_sort | Corti, A. |
collection | PubMed |
description | The structure of circulating chromogranin A (CgA) of phaeochromocytoma patients was characterised and compared with that of CgA extracted from tumours. Size exclusion chromatography experiments provided evidence that CgA is present in the blood of different patients, as well as in tumour extracts, as multiple forms having different hydrodynamic sizes of 600 kDa (CgA-I), 100 kDa (CgA-II) and 55 kDA (CgA-III). The amount of each CgA form as a proportion of the total antigenic material was different in different patients. Western blot analysis of chromatographic fractions indicated that these forms are made up by polypeptides of similar molecular weight (about 60-70 kDa). All CgA forms express the epitopes recognised by two monoclonal antibodies (A11 and B4E11), directed against residues 68-70 and 81-90 of human CgA. However, their relative immunoreactivity was markedly different. No evidence for the presence of multimeric complexes in the CgA-I fraction was obtained by various immunological and biochemical methods. These results suggest that circulating CgA in phaeochromocytoma patients consists of at least three forms that appear to be made up by polypeptides with similar molecular weight and different hydrodynamic properties and immunoreactivity. We hypothesise that different conformations and shapes contribute to the heterogeneity of circulating CgA. IMAGES: |
format | Text |
id | pubmed-2075816 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1996 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20758162009-09-10 Characterisation of circulating chromogranin A in human cancer patients. Corti, A. Gasparri, A. Chen, F. X. Pelagi, M. Brandazza, A. Sidoli, A. Siccardi, A. G. Br J Cancer Research Article The structure of circulating chromogranin A (CgA) of phaeochromocytoma patients was characterised and compared with that of CgA extracted from tumours. Size exclusion chromatography experiments provided evidence that CgA is present in the blood of different patients, as well as in tumour extracts, as multiple forms having different hydrodynamic sizes of 600 kDa (CgA-I), 100 kDa (CgA-II) and 55 kDA (CgA-III). The amount of each CgA form as a proportion of the total antigenic material was different in different patients. Western blot analysis of chromatographic fractions indicated that these forms are made up by polypeptides of similar molecular weight (about 60-70 kDa). All CgA forms express the epitopes recognised by two monoclonal antibodies (A11 and B4E11), directed against residues 68-70 and 81-90 of human CgA. However, their relative immunoreactivity was markedly different. No evidence for the presence of multimeric complexes in the CgA-I fraction was obtained by various immunological and biochemical methods. These results suggest that circulating CgA in phaeochromocytoma patients consists of at least three forms that appear to be made up by polypeptides with similar molecular weight and different hydrodynamic properties and immunoreactivity. We hypothesise that different conformations and shapes contribute to the heterogeneity of circulating CgA. IMAGES: Nature Publishing Group 1996-04 /pmc/articles/PMC2075816/ /pubmed/8611427 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Corti, A. Gasparri, A. Chen, F. X. Pelagi, M. Brandazza, A. Sidoli, A. Siccardi, A. G. Characterisation of circulating chromogranin A in human cancer patients. |
title | Characterisation of circulating chromogranin A in human cancer patients. |
title_full | Characterisation of circulating chromogranin A in human cancer patients. |
title_fullStr | Characterisation of circulating chromogranin A in human cancer patients. |
title_full_unstemmed | Characterisation of circulating chromogranin A in human cancer patients. |
title_short | Characterisation of circulating chromogranin A in human cancer patients. |
title_sort | characterisation of circulating chromogranin a in human cancer patients. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075816/ https://www.ncbi.nlm.nih.gov/pubmed/8611427 |
work_keys_str_mv | AT cortia characterisationofcirculatingchromograninainhumancancerpatients AT gasparria characterisationofcirculatingchromograninainhumancancerpatients AT chenfx characterisationofcirculatingchromograninainhumancancerpatients AT pelagim characterisationofcirculatingchromograninainhumancancerpatients AT brandazzaa characterisationofcirculatingchromograninainhumancancerpatients AT sidolia characterisationofcirculatingchromograninainhumancancerpatients AT siccardiag characterisationofcirculatingchromograninainhumancancerpatients |